ImmuCell Corporation
ICCC
$9.77
-$0.15-1.46%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 30.68M | 29.93M | 27.64M | 27.77M | 28.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.68M | 29.93M | 27.64M | 27.77M | 28.27M |
| Cost of Revenue | 18.31M | 17.19M | 16.20M | 16.40M | 17.69M |
| Gross Profit | 12.37M | 12.75M | 11.45M | 11.37M | 10.59M |
| SG&A Expenses | 7.81M | 6.84M | 5.95M | 5.94M | 5.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2.00M | -- | -- | -- | -- |
| Total Operating Expenses | 26.01M | 26.63M | 25.19M | 25.44M | 26.54M |
| Operating Income | 4.67M | 3.30M | 2.45M | 2.33M | 1.73M |
| Income Before Tax | 853.60K | -523.20K | -1.03M | 2.34M | 1.77M |
| Income Tax Expenses | 66.30K | 22.20K | 11.60K | 14.30K | 11.10K |
| Earnings from Continuing Operations | 0.79 | -0.55 | -1.04 | 2.32 | 1.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 787.50K | -545.30K | -1.04M | 2.32M | 1.76M |
| EBIT | 4.67M | 3.30M | 2.45M | 2.33M | 1.73M |
| EBITDA | 7.05M | 5.88M | 5.18M | 5.03M | 4.43M |
| EPS Basic | 0.09 | -0.06 | -0.11 | 0.26 | 0.19 |
| Normalized Basic EPS | 0.31 | 0.21 | 0.15 | 0.14 | 0.09 |
| EPS Diluted | 0.08 | -0.07 | -0.12 | 0.25 | 0.18 |
| Normalized Diluted EPS | 0.30 | 0.21 | 0.15 | 0.14 | 0.09 |
| Average Basic Shares Outstanding | 36.20M | 36.17M | 36.10M | 35.99M | 35.11M |
| Average Diluted Shares Outstanding | 36.47M | 36.31M | 36.25M | 35.99M | 35.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |